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±4% vs 31 ±5%), 18/22 (82%) had not an EF increase >5 % (p<0.0001 vs Group A),
NYHA class (from 3.5 ±0.5 to 3.2 ±0.8) and exhibited ongoing remodelling (LVEDVI
increased from 106 ±12 ml/m2 to 111 ±8 ml/m2, p=0.04)
The number of scarred segments was directly related (R2 0.52, p<0.0001) while that of
ischemic segments was inversely related to the change in EF (R2 0.46, p<0.0001).
The degree of interventricular dyssynchrony (difference in LV and right ventricular (RV)
mean phase angles) did not change from baseline to the final visit in Group B (11 ±17 vs
12 ±9), while it improved in Group A (13 ±17 vs 9 ±14; p<0.01). The degree of intraven-
tricular dyssynchrony (standard deviation of the mean phase angle) significantly
improved for LV in Group A (54 ±18 vs 51 ±19; p=0.04) but did not change in the LV (57
±14 vs 56 ±19) in Group B.
Conclusion:
Treatment with BiV in patients with ischemic cardiomyopathy and a limited extension of
scarred myocardium improves contractile synchrony, both inter- and LV intraventricular,
EF, quality of life and determines reverse remodelling of the LV
1068-122 Human Fat Tissue-Derived Stem Cells Show 
Cardiomyocytic Differentiation After Coculture
Kai Pinkernell, Christian Valina, William C. Claycomb, Jakob Reiser, R. Edward 
Newsome, Jr., Eckhard Alt, Tulane University, School of Medicine, New Orleans, LA, 
Louisiana State University, New Orleans, LA
Introduction: Cells isolated from subcutaneous fat tissue (SFT) can give rise to cells
from all three germ layers. So far differentiation into a cardiomyocyte (CM) lineage by
means of co-culturing has not been shown for cells isolated from human SFT. The acces-
sibility and obtainable cell numbers would make SFT an excellent source of cells for tis-
sue repair after myocardial infarction. Methods: CM from neonatal rat hearts were
isolated on day 1 after birth, digested with Collagenase (10mg/ml) and cultured for 1 day
under standard conditions. SFT from patients undergoing liposuction was collected and
digested with Collagenase for 90 minutes to obtain a single cell suspension. Cells were
plated under standard conditions and transfected with a lentivirus encoding eGFP. SFT
cells were then co-cultured with the neonatal rat CM in a 1:1 ratio. FACS analysis of
adherent SFT cells was done at day 1 and 5 prior to co-culture for CD34, CD45, CD105,
and CD117. Immunohistochemistry of cardiac specific Titin, Troponin T and eGFP of co-
cultured cells was done after 14 days or total RNA was harvested and an RT-PCR was
performed. Results: More than 1.3x106 cells/gram could be isolated routinely from SFT
and 30% did adhere to tissue culture plastic. A FACS analysis of the adhering SFT cells
showed an expression of CD 34 (48% +/- 9) and CD45 (6%+/-2) after 1 day in culture
which dropped to undetectable levels after 5 days. CD105 expression was 50% (+/-8, day
1) and increased to 97% (+/-2, day 5). CD117 could not be detected at any time. The co-
cultures were dispersed after 14 days and re-plated. Immunohistochemistry staining
showed dual positivity of SFT for eGFP and Titin but not for Troponin T. This was con-
firmed in the RT-PCR reaction with human specific Primers for Titin that do not cross
react with the rat CM. The RNA expression level in the CM and SFT coculture was 11 fold
above control (corrected for GAPDH). Conclusion: SFT cells show the predominantly
endothelial cell marker CD105 after 5 days in culture and are void of CD34,45 or CD117.
Direct cell-cell contact through co-culture between SFT cells and rat CM leads to an early
cardiomyocytic phenotype that expresses the sarcomeric protein Titin as shown by
immunohistochemistry and RT-PCR.
1068-123 Akinetic Segments of Myocardial Infarction Contain 
Contracting Myocytes: A Finite Element Model Study
Alan B.C. Dang, Julius M. Guccione, Jacob M. Mishell, Peng Zhang, Arthur W. Wallace, 
Robert C. Gorman, Joseph H. Gorman, III, Mark B. Ratcliffe, San Francisco Veterans 
Affairs Medical Center, San Francisco, CA, University of California, San Francisco, San 
Francisco, CA
Background:Infarcted segments of myocardium demonstrate a range of functional impair-
ment. The properties that determine the severity of dysfunction are not fully understood.
Using a finite element model, we sought to better define the relative contributions of pas-
sive material properties (stiffness) versus active properties (contracting myocytes) in
determining regional wall motion. We tested the hypothesis that in order for a segment to
be akinetic and not dyskinetic, it must contain contracting myocytes. Methods: Using two-
dimensional echocardiographic images from a reperfused ovine anteroapical infarct, we
developed a three-dimensional finite element mesh of the left ventricle. The model
describes both diastolic material properties defined by a constant, C, and systolic myo-
cardial material properties defined by isometric tension, Tmax. A reduction in the ability of
the infarcted region to develop active stress was accomplished by scaling the parameter
Tmax to represent the percentage of contracting myocytes between 0% and 100%. The
simulated change in wall thickness between end-diastole and end-systole was measured
using the fractional change of average radial strain (RS). Akinesis was defined as an
average RS between -0.01 and +0.01, where a more positive or negative value repre-
sents hypokinesis or dyskinesis, respectively. The diastolic and systolic properties neces-
sary to produce akinesis were determined using an iterative process.We then modeled
an infarct with no contracting myocytes and increased the diastolic stiffness required for
akinesis until RS fell between -0.01 and +0.01. Results: As stiffness, C, was increased
from normal (0.876 kPa) to ten times normal (10 kPa), the percentage of Tmax necessary
to achieve RS between -0.01 and +0.01 increased from 20-50 %. When the percentage
of contracting myocytes was assumed to be zero, a stiffness of C=250 kPa was neces-
sary to achieve akinesis. Conclusion: In this finite element model of left ventricular myo-
cardial infarction, if wall stiffness is less than 250 times normal, the presence of
contracting myocytes in the infarct zone is necessary to prevent dyskinetic wall motion.
1068-124 Nonviral FasL Protects Allogeneic Myoblasts Against 
Cell Death in Cardiomyogenesis
Yoshihisa Morimoto, Jamie M. Bergen, Bryce H. Davis, Ewout-Jan van den Bos, Doris A. 
Taylor, Duke University Medical Center, Durham, NC
Background: FasL, which promotes T-cell apoptosis through interaction with the death
receptor Fas, has been proposed to immunoprotect allotransplanted cells. However, suc-
cess with this strategy has been limited in part due to inflammatory side effects of viral
vectors. We hypothesize that overexpression of FasL in myoblasts via a non-viral vector
will provide protection of allotransplanted cells in heart.
Methods: C2C12 myoblasts were stably transfected with FasL and co-cultured with acti-
vated T-cells to determine FasL activity. T-cell apoptosis was examined by annexin V
expression. In vivo, control animals received untransfected DAPI-labelled myoblasts
(2x106), while treated animals (FasL group) received transfected labeled myoblasts
where 25% expressed FasL. Myoblasts were injected into cryoinjured myocardium, the
kidney capsule or subcutaneously (n=12 each). We evaluated DAPI-positive cell survival
and engraftment by histology at 1 hour and 3, 10 or 14 days post-injection.
Results: FasL transfected myoblasts induced a fourfold higher apoptosis rate in T-cells
than untreated myoblasts in vitro (23.0±2.51% vs 7.05±3.93%, P<0.001). In vivo, FasL
protected allogenic cells after injection into cryoinjured myocardium up to 14 days
(21±8.1/HPF vs 8.9±9.1 control, P<0.05). Concurrently, the maximum infarct diameter
was reduced (0.25±0.02 vs 0.29±0.03 mm; P<0.05) and infarct wall thickness was
increased (0.11±0.03 vs 0.07±0.03 mm; P<0.05). Similarly, FasL cells protected allo-
genic cells at 1h, 3d and 10d after subcutaneous injection as compared to controls
(251±6.0, 232±7.1 and 231±6.8 /HPF for FasL vs. 49±2.6, 0, 0 /HPF for controls,
P<0.001). Surprisingly, FasL did not protected allogenic cells after injection under the kid-
ney capsule.
Conclusion: Functional FasL, delivered non-virally, can more than double survival of allo-
genic cells after transplantation into injured myocardium or subcutaneously. FasL might
be a useful tool in allogenic cell therapy.
1068-125 Cyclic Stretch of Adult Human Mesenchymal Stem Cells 
Induces Expression of Early Cardiac and Neuronal 
Genes
Sunil Rangappa, Andrew S. Wechsler, J. Yasha Kresh, Drexel University College of 
Medicine, Philadelphia, PA
Background: Human mesenchymal stem cells have shown to be plastic and amenable
to transformation into cardiomyocytes. Myocardial regeneration using direct injection of
stem cells into infarcted myocardium results in low yield of differentiated cardiomyocytes.
Alternately, stem cells have been preprogrammed using chemicals, growth factors, and
co-culture of cells into cardiomyocytes in vitro. We explored the role of cyclic stretch on
human mesenchymal stem cells (hMSCs) as a stimulus to promote transdifferentiation.
Methods: hMSC were cultured in 6 well plates and subjected to programmable square
cyclic stretch at 1 Hz using the Flexercell system with 4% and 8% elongation of cells
alternating every 12 hours for 7 days in a humidified incubator with 5% CO2 at 37oC. Total
RNA was isolated from the stretched hMSC and unstretched control experiments using
microarray (Hu133A gene chips, Affymetrix Inc) and lineage specific gene expression
was studied. Genes were profiled in triplicate for cardiogenic, adipogenic, neurogenic,
osteogenic and skeletal lineage.
Results: The data was normalized and lineage specific genes were analyzed using
Gene Spring V.5.0. Induction of synaptobrevin, macrotubule associated protein (MAP-2),
and Galactocerebroside genes indicating early neurogenic lineage was observed, in
addition there was also concurrent expression of Connexin-43 and BMP-2 indicative of
early cardiogenic lineage. In contrast, there was no expression of adipogenic, osteogenic
and skeletal genes.
Conclusions: These data suggest that adult human bone marrow stem cells are plastic
and mechanical stretch bioengineers hMSC transdifferentiation to early cardiogenic and
neurogenic lineage. This technique of preprogramming stem cells in vitro could poten-
tially be used to increase high yield of lineage specific cells before cellular cardiomyo-
plasty.
1068-126 Cultured Adipose Tissue-Derived Stromal Cells Express 
the Stem Cell Marker CD34 and Show Evidence of 
Differentiation Into a Cardiomyocyte Phenotype
Jalees Rehman, Rafat Siddiqui, Jingling Li, Dmitry Traktuev, Stephanie Merfeld-Clauss, 
Keith L. March, Indiana University, School of Medicine, Indianapolis, IN
Background: Autologous cell therapy using pluripotent cells for cardiac repair and
regeneration in patients with cardiomyopathy is limited by the fact that the required cell
numbers often exceed the number of available pluripotent cells. We have recently shown
that a substantial proportion of non-adipocyte stromal cells in adipose tissue express the
stem/progenitor cell marker CD34. We therefore examined whether adipose stromal cells
(ASCs) would retain this marker in culture and whether they could differentiate into a car-
diomyocyte phenotype in vitro.
Methods: Subcutaneous adipose tissue biopsies or lipospirates were obtained from vol-
unteers. The stromal fraction cells were cultured in EBM-2 or EGM-2 medium (Clonetics-
Cambrex). The expression of CD34 was assessed on days 2, 4, 6 and 8 by flow cytome-
try. To assess differentiation of ASCs, they were labeled with the red fluorescent dye DiI
(Molecular Probes) and added to culture wells containing neonatal rat cardiomyocytes
(CMCs). The co-culture was observed for four days to identify spontaneously beating
cells. At the end of the co-culture period, cells were fixed and stained for cardiac-specific
alpha-actinin and the nuclear stain DAPI.
Results: The expression of the stem/progenitor cell marker CD34 on human ASCs was
present at consistently high levels during the first week of culture (Day 2: 95%, Day 4:
91%, Day 6: 89%, Day 8: 77%). Multiple ASCs showed evidence of spontaneous beating
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in co-culture with rat cardiomycytes. Spontaneous beating of ASCs was most pro-
nounced when there was cell-cell contact with rat CMCs. While all of the non-red cells
with typical rat CMC morphology stained positive for cardiac-specific alpha-actinin, few
fluorescent ASCs were also positive for cardiac-specific alpha-actinin.
Conclusions: Our experiments suggest that human subcutaneous adipose tissue con-
tains cells which in culture express the stem cell marker CD34 and have potential to
acquire a cardiomyocyte phenotype. Considering that large quantities of fat can be easily
harvested from patients, cell therapy using autologous ASCs for cardiac regeneration or
repair may represent a novel therapeutic option for patients with cardiomyopathy.
1068-127 Ischemic Precondition Improves Performance of the 
Hearts With Coronary Delivery of Embryonic Stem 
Cells: Assessment by a Langendorff Perfusion Model
Jing Lin, Shu Li, Eric Lenehan, Mitra Rajabi, Rosalinda Madonna, Corina Rosales, 
James T. Willerson, Yong J. Geng, The University of Texas Medical School at Houston, 
Houston, TX, Texas Heart Institute, Houston, TX
Background: Intracoronary stem cell perfusion is a novel therapy for heart failure. How-
ever, concern has been raised about the biosafety of this therapy. This study aimed at
analyzing functional and metabolic alterations in the hearts perfused with embryonic
stem cells (ESCs).
Methods: Hearts of C57BL/6J mice were perfused with modified Krebs-Henseleit buffer
on a Langendorff device. Ischemia-preconditioning (IPC) was performed. Thereafter, flu-
orochrome tagged murine D3 ESCs were transfused and hemodynamic parameters,
e.g., coronary flow (CF), heart rate (HR), left ventricular peak pressure (LVP), +dp/dtmax,
and -dp/dtmax, were recorded. Coronary effluents were collected to determine cardiac
troponin I (cTnI). After perfusion, the hearts were fixed and subjected to histopathological
studies. 
Results: Murine hearts with coronary ESC perfusion at 106 cells/ml/min or less showed
no major changes in contractility and rhythm. However, with cell concentration increase
(2.5 ~ 5 x 106 cells/ml/min), the hearts were dysfunctional, with declines in all hemody-
namic parameters and marked increase in cTnI in coronary effluents. Interestingly, IPC
significantly reduced the adverse impact of high ESC perfusion by nearly 50% compared
to heart perfusion without IPC. Improved morphology occurred in IPC myocardium with
ESC perfusion.
Conclusions: Perfusion of ESC at high concentrations may cause cardiac dysfunctions.
IPC may increase tolerance to stem cell perfusion and improve performance of the
hearts.
1068-128 Ranolazine Inhibits Late Sodium Current in Isolated Left 
Ventricular Myocytes of Dogs With Heart Failure
Albertas I. Undrovinas, Nidas A. Undrovinas, Luiz Belardinelli, Hani N. Sabbah, Henry 
Ford Heart and Vascular Institute, Detroit, MI, CV Therapeutics, Palo Alto, CA
Background: We recently reported the existence of novel, ultraslow late sodium current
(INaL) in left ventricular (LV) myocytes isolated from failing human and dog hearts. Aug-
mented INaL has been implicated in ventricular repolarization abnormalities in chronic
heart failure (HF). In the present study we sought to determine the effects of ranolazine
(RAN), a novel anti-ischemic drug, on peak (INaT) and late INaL, action potential (AP)
duration (APD), and early afterdepolarizations (EAD’s) in LV myocytes isolated from dogs
with chronic HF.
Methods: Experiments were carried out in mid-myocardial LV myocytes isolated from the
hearts of 6 dogs with chronic HF produced by the intracoronary microembolization. AP’s
were recorded using the β-escin perforated patch method at a frequency of 0.5 Hz and
35oC. Both INaT and INaL were recorded by a conventional whole-cell patch-clamp tech-
nique. Amplitude and decay of INaL were measured at 200 ms after the onset of a 2 sec-
ond-long depolarization to -30 mV at 0.1 Hz.
Results: RAN, at a concentration of 5 µmol/L, reversibly shortened the APD from a base-
line value of 556 ± 53 ms to 316 ± 34 ms (mean ± SEM, n=8 cells, P<0.05). RAN also
decreased APD dispersion and suppressed EADs. At the same concentration (5 µmol/L),
RAN shifted the mid-point steady-state availability of INaL by -7.7±1.2 mV (n=5 cells). The
potency (IC50 value) of RAN to cause resting block of INaL, assessed by a single-site
binding model, was 6.7 µM (n=6 cells). In contrast, 5µmol/L of RAN did not significantly
inhibit INaT. The IC50 for inhibition by RAN of INaT was 244 µmol/L (n=14 cells). RAN did
not affect the decay time course of INaL.
Conclusion: In these experimental conditions, RAN is approximately a 36-fold more
potent blocker of late INa than peak INa, and reverses the ventricular repolarization abnor-
malities (APD prolongation and EADs) of failing myocytes. These findings suggest that
ranolazine, by inhibiting INaL, may suppress ventricular arrhythmic activity associated
with augmented INaL during repolarization of the action potential in HF.
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1069-105 50-Year Heart Failure Mortality for England and Wales
Steven Sutcliffe, Des Watson, Charles Phillips, Christopher Davidson, Brighton and 
Sussex Universities Hospital, Brighton, United Kingdom
Aim: To analyse heart failure mortality trends for England and Wales over fifty years, from
1951 to 2000.
Design: A retrospective observational study using death certificate and population data
from the Office for National Statistics for England and Wales.
Results: Unadjusted heart failure deaths rose by 3.3 from approximately 3400 in 1951 to
11400 in 1974. Since then, heart failure deaths have fallen by approximately 25% to 8600
in 2000. Throughout this period, the number of people in the Western world surviving
beyond 70 years has steadily increased and so it would be expected that the number of
heart failure deaths would increase too. However, even when heart failure mortality is
standardised to allow for changes in the age, sex and size of the population, there was
approximately a 2.2 rise in mortality from 1951 to the mid-70’s and since then, there has
been a substantial and sustained decline in mortality of approximately 55% by 2000. The
unadjusted female heart failure death rate has been between 1.5 and 2 times that of
males since the early 70’s. However, this higher mortality rate is much less marked when
the differences between the age distribution and sizes of the male and female popula-
tions are taken into account. When compared with trends in mortality for coronary artery
disease the changes with time and by age group are remarkably similar.
Conclusion: The trends in heart failure mortality for England and Wales over 50 years
may reflect genuine changes in disease incidence, influenced by current changes in life-
style and the medical management of cardiac disease. These changes are similar to
those seen in coronary artery disease. The data available cannot estimate the absolute
incidence of deaths involving heart failure because of death certificate completion and
the trends in heart failure diagnosis over time.
1069-106 Deaths From Heart Failure in the Era of the Implantable 
Defibrillator
Jeffrey J. Teuteberg, Usha Tedrow, Eldrin F. Lewis, Anju Nohria, Sui W. Tsang, James C. 
Fang, Michael Givertz, John A. Jarcho, Gilbert H. Mudge, Kenneth L. Baughman, Lynne 
W. Stevenson, Brigham and Women's Hospital, Boston, MA
Background: Despite the growing number of indications for implantable cardioverter-
defibrillators (ICD) and the improving survival with heart failure (HF), morbidity and mor-
tality from progressive HF remain substantial.
Methods: To determine the prevalence of ICDs in patients dying with advanced symp-
tomatic HF, we reviewed all of the patients followed in the HF program with an ejection
fraction (EF) less than or equal to 35% and recent NYHA class III/IV symptoms who died
in the hospital or after discharge with hospice between 1/1/00 and 9/1/03.
Results: There were total of 126 deaths, of which 68 (54%) met the criteria for entry into
the study (57 patients died in the hospital, 9 patients died in hospice). Patients had HF for
a mean of 5.8 years, had a mean age of 61 years, and 75% were men. The mean EF was
19% and moderate to severe right ventricular dysfunction was present in 62%. Beta-
blockers and/or amiodarone were taken by 75% of patients. Ischemic cardiomyopathies
(CM) accounted for 55% of patients, of whom 79% had prior bypass. The mean of the
worst laboratory values in the last six months of life include a sodium of 127, blood urea
nitrogen of 97 and creatinine of 3.7.
Of the 68 deaths, 34 (50%) had an ICD, three of whom also had biventricular pacing. The
prevalence of ICDs was 47% in patients with ischemic CM and 53% in patients with
nonischemic CM. Advance directives specified limits on resuscitation in 24 (71%), of
which 13 (54%) had defibrillation inactivated (10/22 in hospital, 3/3 in hospice), but only a
median of 1 day prior to death. Overall, the ICDs were implanted a median of 21.5
months (range 1-144) prior to death, but 11 (32%) were implanted less than 1 year before
death and 6 (18%) less than 6 months before death (5/6 of these were implanted for pri-
mary prevention).
Conclusions: In patients with advanced HF, there is a high prevalence of ICDs, regard-
less of the etiology of HF. However, the benefit from preventing sudden death may be
diminished as the likelihood of terminal hemodynamic deterioration increases. Therefore,
management of ICDs will become an increasingly important aspect of care at the end of
life.
Table 1. Hemodynamic and Biochemical Alterations at 30 minute after Stem Cells 
Perfusion
ESC Perfusion without IPC
( X 106 cells/ml/min)
ESC Perfusion 
with IPC
( X 106 cells/ml/
min)
0 1.0 2.5 5.0 5.0
CF -10.8
+ 7.2%
-22.2
+ 28.0%
-55.0
+ 32.2%
-63.6
+ 29.7%
-31.4
+ 16.7%
HR -10.2
+ 11.8%
-22.4
+ 24.5%
-19.4
+ 23.7%
-49.7
+ 22.0%
-24.9
+ 10.3%
LVP -1.9
+ 20.7%
-7.0
+ 19.1%
-30.7
+ 24.5%
-50.2
+ 39.0%
-24.4
+ 32.9%
+dp/dt +2.6
+ 15.7%
-7.6
+ 41.3%
-40.4
+ 27.0%
-57.6
+ 36.3%
-32.8
+ 25.1%
-dp/dt -12.8
+ 22.3%
-26.0
+ 24.8%
-50.9
+ 23.5%
-69.1
+ 29.8%
-45.2
+ 20.8%
cTnI +20.9
+ 67.7%
+42.6
+ 70.8%
+256.6
+ 93.1
+1403.4
+ 849.9%
+6.9
+ 20.5%
